

REMARKS

Entry of this amendment and reconsideration of this application, as amended, is respectfully requested.

It is believed that the amendments to SEQ ID NO: 1 are fully supported by example 5 of the provisional application, which was incorporated by reference (see page 1 of the specification). Thus, it is believed that Applicant is entitled to the provisional filing date of April 22, 2002, rendering Chan et al. unavailable as a reference. Thus, all rejections based on Chan et al. must be withdrawn.

Since all rejections in the final office action of March 11, 2008 were based at least in part by Chan, all rejections are believed to now be rendered moot.


In view of the foregoing, allowance is respectfully requested.

Please charge the extension fee and any other fee due to Deposit Account No. 50-0624 under Order No. LBNL-201 US (10412981) from which the undersigned is authorized to draw.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

By:


James R. Crawford
Registration No. 39,155
666 Fifth Avenue
New York, New York 10103-3198

(212) 318-3000
(212) 318-3400 (fax)


VIA Express Mail

I hereby certify that this correspondence is being deposited with the U.S. Postal Service by Express Mail: EM 155788381 US an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22313-1450 on the date shown below:

Date: July 9, 2008


Natalia Platonova

LBNL-201-US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Chen, et al.

Serial No : 10/511,561

Filed : October 15, 2004

For : DNA DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT PHOSPHORYLATION SITES AND ANTIBODIES THERETO

Art Unit : 1644

Examiner : Yunsoo Kim

July 8, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

STATEMENT PURSUANT TO 37 CFR 1.823(B) AND AMENDMENT

Dear Sir:

Please amend the above-identified patent application as follows:

IN THE SEQUENCE LISTING

Please replace the present sequence listing with the attached sequence listing.

REMARKS


Submitted herewith for filing in connection with the above-referenced patent application is a computer readable copy of an amended Sequence Listing for the above-identified patent application. SEQ ID NO: 1 has been amended as set forth in the amendment to the specification in the Amendment with RCE submitted herewith, i.e., to delete the first amino acid in the originally filed Sequence Listing. No new matter is believed to be added by way of this amendment.

Please replace the present Sequence Listing with the attached amended Sequence Listing. A CD with the electronic version of the Sequence Listing is also submitted herewith.

I hereby state that I have reviewed the paper copy of the Sequence Listing, as required by 37 C.F.R. § 1.821(c), and have reviewed the computer readable form of the Sequence Listing, as required by 37 C.F.R. § 1.821(e), and that the content of the paper and computer readable copies for the above-referenced patent application are the same as required by 37 C.F.R. § 1.821(f).

Early favorable consideration of the patent application is respectfully solicited.

Respectfully submitted,

By 
James R. Crawford
Reg. No. 39,155
Fulbright & Jaworski, L.L.P.
Attorneys for Applicant

666 Fifth Avenue
New York, New York 10103
(212) 318-3000
(212) 318-3400 (Fax)